A team of Ballard Spahr attorneys represented Cephalon, Inc., in its merger agreement under which it will acquire all of the outstanding capital stock of privately held Gemin X Pharmaceuticals, Inc. Cephalon is acquiring the biopharmaceutical company for $225 million cash on a cash-free, debt-free basis. The agreement is subject to the receipt of necessary regulatory approvals.